Last €2.08 EUR
Change Today +0.153 / 7.92%
Volume 0.0
XS5A On Other Exchanges
As of 1:03 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

echo therapeutics inc (XS5A) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/19/15 - €2.61
52 Week Low
09/24/14 - €0.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ECHO THERAPEUTICS INC (XS5A)

Related News

No related news articles were found.

echo therapeutics inc (XS5A) Related Businessweek News

No Related Businessweek News Found

echo therapeutics inc (XS5A) Details

Echo Therapeutics, Inc. is engaged in the development of transdermal skin permeation and diagnostic medical devices. It is developing Symphony CGM system (Symphony), a needle-free wireless continuous glucose monitoring system for use in hospital critical care units; and Symphony SkinPrep system, a component of its Symphony for enhanced skin permeation that enables extraction of analytes, such as glucose. The company is also engaged in the development Durhalieve, an AzoneTS formulation of triamcinolone acetonide that has completed Phase III clinical trials for the treatment of corticosteroid-responsive dermatoses. It has a licensing agreement with Ferndale Pharma Group, Inc. to develop, market, sell, and distribute Prelude SkinPrep system for skin preparation prior to the application of topical anesthetics prior to a range of needle-based medical procedures in North America, the United Kingdom, South America, Australia, New Zealand, Switzerland, and other portions of the European Community; a license agreement with Handok Pharmaceuticals Co., Ltd. to develop, use, market, import, and sell Symphony for continuous glucose monitoring for use by medical facilities and/or individual consumers in South Korea; and a license, development, and commercialization agreement with Medical Technologies Innovation Asia, Ltd. The company was founded in 1989 and is headquartered in Philadelphia, Pennsylvania.

28 Employees
Last Reported Date: 03/28/14
Founded in 1989

echo therapeutics inc (XS5A) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

echo therapeutics inc (XS5A) Key Developments

Echo Therapeutics, Inc. Engages BDO USA, LLP as Independent Registered Public Accounting Firm

On February 5, 2015, Echo Therapeutics, Inc. engaged BDO USA, LLP as its independent registered public accounting firm.

Echo Therapeutics, Inc. Announces Audit Committee Appointments

On January 5, 2015, the Board of Directors of Echo Therapeutics, Inc. appointed Shepard Goldberg and Michael Goldberg to the Audit Committee, both of whom are independent directors.

Echo Therapeutics Receives Non-Compliance Notice From NASDAQ

On January 30, 2015, Echo Therapeutics, Inc. received a letter, dated January 30, 2015, from NASDAQ, indicating that the Company no longer complies with NASDAQ’s audit committee requirements set forth in NASDAQ Listing Rule 5605. Such rule requires that the Audit Committee of the Company have a minimum of three members and be composed only of independent directors. As previously reported, on December 31, 2014, Vincent P. Enright, William F. Grieco and James F. Smith resigned from the Board of Directors of the Company, as well as its Audit Committee. As a result, the Audit Committee had no members as of Decembers 31, 2014. On January 5, 2015, the Board of Directors appointed Shepard Goldberg and Michael Goldberg to the Audit Committee, both of whom are independent directors. NASDAQ provided to the Company a cure period in order to regain compliance as follows: until the earlier of the Company’s next annual shareholders’ meeting or December 31, 2015; or if the next annual shareholders’ meeting is held before June 29, 2015, then the Company must evidence compliance no later than June 29, 2015. The Company intends to add at least one additional independent member to the Audit Committee by the date required by Nasdaq Listing Rule 5605.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XS5A:GR €2.08 EUR +0.153

XS5A Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $47.37 USD -0.24
Bayer AG €131.62 EUR +0.108
Johnson & Johnson $102.51 USD -0.29
Roche Holding AG SFr.258.80 CHF -0.20
View Industry Companies

Industry Analysis


Industry Average

Valuation XS5A Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,768.8x
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,678.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ECHO THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at